Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Apple Turns 50: From Garage Startup to AI Crossroads 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
BRISBANE, Calif., June 26, 2017 -- KaloBios Pharmaceuticals, Inc. (OTCQB: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, today announced it has been approved for trading its stock on the OTCQB® Venture Market, upgrading from the Pink Market®.
The OTCQB is recognized as an Established Public Market by the U.S. Securities and Exchange Commission. The OTCQB trading standards require that companies be current in their regulatory filings, complete an annual verification and management certification, and have a minimum $0.01 bid price.
“Trading on the OTCQB is another incremental step forward in our strategy to improve the financial foundation of KaloBios, enhance liquidity in our stock and continue to build more trust in the investment community,” said Cameron Durrant, MD, chairman and CEO of KaloBios. “Meantime, we will continue to pursue the key corporate goal of uplisting to a national securities exchange.”
Investors and all stakeholders can find more information about the OTCQB market, quotes and other details at www.otcmarkets.com.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTCQB: KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Lenzilumab has potential for treatment of various rare diseases, including hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
